Archive: November 2016

Optimal Treatment of Unresectable Stage III Non–Small Cell Lung Cancer

Clinical Advances in Hematology & Oncology Volume 14, Issue 11, November 2016 Jeffrey D. Bradley, MD S. Lee Kling Professor of Radiation Oncology Alvin J. Siteman […]

The Use of Drug Transporters as Therapeutic Targets

Kathleen M. Giacomini, PhD

H&O  What is the role of transporters in cell biology? KG  Transporters are proteins that play a role in bringing small molecules—such as endogenous compounds, vitamins, […]

Adjuvant Treatment for Renal Cell Carcinoma: Do We Finally Have a Major Breakthrough?

Clinical Advances in Hematology & Oncology Volume 14, Issue 11, November 2016 Devin N. Patel, MD, Robert A. Figlin, MD, and Hyung L. Kim, MD The […]

Immunotherapy for the Treatment of Breast Cancer: Checkpoint Blockade, Cancer Vaccines, and Future Directions in Combination Immunotherapy

Heather L. McArthur, MD, MPH, and David B. Page, MD

Abstract: Immunotherapy encompasses both vaccines that direct immune responses to tumor-associated antigens, and checkpoint blocking antibodies that inhibit immune system suppression by targeting key pathways mediated […]

When to Initiate Treatment in Myelofibrosis

Claire Harrison, MD

H&O  What are the characteristics of myelofibrosis? CH The cardinal features of the blood cancer myelofibrosis are splenomegaly, fibrosis in the marrow, and either myeloid proliferation […]

New Treatments for Bladder Cancer

Noah M. Hahn, MD

H&O  How common is bladder cancer? NH  Bladder cancer is very common in the United States; it is the fifth most common cancer diagnosed in this […]

Should Treatment of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Be Intensive?

Clinical Advances in Hematology & Oncology Volume 14, Issue 11, November 2016 Counterpoints: Approximately 20% to 30% of adults diagnosed with acute lymphoblastic leukemia are positive […]

What Hematologists Need to Know About Acute Hepatic Porphyria

Manisha Balwani, MD, MS

H&O  What is porphyria? MB The porphyrias encompass a group of inherited metabolic disorders that result from a deficiency of one of the enzymes in the […]

Guideline Recommendations for the Prophylaxis of Invasive Aspergillosis in AML

Clinical Advances in Hematology & Oncology Volume 14, Issue 11, November 2016 Eunice S. Wang, MD Chief, Leukemia Service Professor of Oncology, Department of Medicine Roswell […]

Hem/Onc News

Clinical Advances in Hematology & Oncology Volume 14, Issue 11, November 2016 Devon Schuyler Daratumumab Improves Progression-Free Survival in Relapsed/Refractory Myeloma The addition of daratumumab (Darzalex, […]

Letter From the Editor: Ode to Bob

Clinical Advances in Hematology & Oncology Volume 14, Issue 11, November 2016 May your song always be sung / May you stay forever young. —Bob Dylan […]

Back to Archive